These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35360461)

  • 61. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Measles, mumps and rubella vaccination status of school beginners in Munich].
    Markuzzi A; Schlipköter U; Weitkunat R; Meyer G
    Soz Praventivmed; 1997; 42(3):133-43. PubMed ID: 9334085
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The active offering of measles, rubella and mumps vaccine in new mothers: the experience of health facilities in one of the Local Health Unit of Rome, Lazio, Italy].
    Santoro V; Pettinicchio V; Lancia A; Vazzoler C; De Luca F; Franco E
    Ig Sanita Pubbl; 2016; 72(6):589-597. PubMed ID: 28214912
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement.
    Czajka H; Czajka S; Dyląg KA; Borek E; Kuchar E
    Adv Exp Med Biol; 2019; 1153():101-107. PubMed ID: 30758772
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Jefferson T; Rivetti A; Price D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children.
    Mohta A; Kushwaha RK; Gautam U; Sharma P; Nyati A; Jain SK
    Pediatr Dermatol; 2020 Sep; 37(5):853-859. PubMed ID: 32681688
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
    Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000.
    Halsey NA; Hyman SL;
    Pediatrics; 2001 May; 107(5):E84. PubMed ID: 11331734
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
    Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
    Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
    Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
    Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
    [TBL] [Abstract][Full Text] [Related]  

  • 76. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
    American Academy of Pediatrics. Committee on Infectious Diseases
    Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
    Singh R; John TJ; Cherian T; Raghupathy P
    Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.